Ask AI
ProCE Banner Activity

Experts Discuss CELMoD Agents for Multiple Myeloma

Podcast

Listen to expert faculty as they discuss the use of CELMoD agents to manage multiple myeloma, including a recent approval, mechanism of action and differentiation from IMiDs, current data, and potential treatment settings.

Released: August 20, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the impact of binding affinity and potency on the antimyeloma activity of individual novel agents and approaches

  • Evaluate the potential clinical implications of emerging data for novel therapies on treatment of multiple myeloma across the disease continuum

  • Identify patients with multiple myeloma who may be eligible for and likely to benefit from enrollment on clinical trials investigating novel therapies

Financial Disclosures

Primary Author

Meletios-Athanasios (Thanos) C. Dimopoulos, MD: consultant/advisor/speaker: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, GSK, Janssen, Menarini, Regeneron, Sanofi, Swixx, Takeda.

María-Victoria Mateos, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Kite, Menarini Stemline, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi.